Exosomes mediate intercellular microRNA delivery between hepatic stellate cells (HSC), the principal fibrosis-producing cells in the liver. The purpose of this study was to identify receptors on HSC for HSC-derived exosomes, which bind to HSC rather than to hepatocytes. Our findings indicate that exosome binding to HSC is blocked by treating HSC with RGD, EDTA, integrin avo rb1 siRNAs, integrin avb3o ra5b1 neutralizing antibodies, heparin, or sodium chlorate. Furthermore, exosome cargo delivery and exosomeregulated functions in HSC, including expression of fibrosis-or activationassociated genes and/or miR-214 target gene regulation, are dependent on cellular integrin avb3, integrin a5b1, or heparan sulfate proteolgycans (HSPG). Thus, integrins and HSPG mediate the binding of HSC-derived exosomes to HSC as well as the delivery and intracellular action of the exosomal payload.
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Keywords: connective tissue growth factor; fibrogenesis; hepatic fibrosis; microRNA; microvesicle Hepatic stellate cells (HSC) account for 3-5% of the cells in the liver and, under normal circumstances, are a quiescent cell type that plays a role in vitamin A storage and regulation of vascular tone [1] . During liver injury, HSC undergo an activation process that results in important alterations in their phenotype and function that are central to wound healing, including enhanced proliferation, migration, increased contractility due to expression of a smooth muscle actin (aSMA), and production of matrix proteins (collagen) [2] . In acute injury, this activation is transient and results in the deposition of a provisional matrix scaffold to support hepatocyte proliferation and repopulation. Chronic liver injury leads to a perpetuation of the activated HSC phenotype resulting in unabated collagen production, causing fibrous scar material to be deposited which, over time, can seriously impede normal liver function [3] . Fibrogenic pathways in activated HSC are mediated by transforming growth factor-beta or connective tissue growth factor (CCN2; also known as CTGF) which are produced by activated HSC as well as by other liver cell types after injury [1] [2] [3] [4] [5] [6] . Pathways of fibrogenesis in HSC have become the focus of a concerted effort to understand the underlying mechanisms involved and have led to the identification of rational targets for therapeutic intervention [7] [8] [9] [10] ; the importance of these advances is underscored by the paucity of approved antifibrotic drugs despite the prevalence of liver fibrosis, which affects millions of people globally.
Connective tissue growth factor production in quiescent HSC is directly suppressed by the binding to the Abbreviations CCN2, connective tissue growth factor; HSC, hepatic stellate cell; HSPG, heparan sulfate proteoglycans; miR, microRNA; siRNA, small interfering RNA; aSMA, alpha smooth muscle actin; UTR, untranslated region.
CCN2 3
0 -UTR of microRNA (miR) -214 or miR199a-5p each of which is transcribed downstream of the Twist1 transcription factor [11] [12] [13] . This inhibitory Twist1-miR-214-miR-199a-5p pathway is suppressed in activated HSC, allowing CCN2 to be produced and to drive fibrogenesis in the cells. Twist1 or miR-214/199a-5p may also be exported from HSC in exosomes [11] [12] [13] , membranous nanovesicles that arise by inward budding of multivesicular bodies and which are released extracellularly when multivesicular bodies fuse internally with the plasma membrane. Exosomes traverse the intercellular space and may be taken up by neighboring cells, including HSC themselves [14] . Exosomes contain a complex mixture of miRs, mRNA and proteins that reflect the transcriptional and/or translational activity of the donor cell and which may cause epigenetic reprogramming and phenotypic alterations in recipient cells [14] [15] [16] . Exosomes from quiescent HSC are intercellularly shuttled to activated HSC in which the activated phenotype is then suppressed [12, 13, 17] . This is due, in part, to exosomal delivery of Twist1 or miR-214/199a-5p that cause, respectively, enhanced expression of miR-214 or reduced expression of CCN2, the net effect of which is to dampen CCN2-dependent fibrogenic pathways in activated HSC [12, 13, 17] . Similarly, CCN2 can also be exosomally shuttled from activated HSC and delivered to other HSC recipients in which it is biologically active and can drive fibrogenesis [18] . Collectively, the participation of neighboring HSC in exosomal communication networks represents a mechanism by which fibrogenic signaling is fine-tuned and up-or down-regulated according to the differential activation status of recipient and donor cells. Despite these advances, exosomes represent a largely unexplored component of fibrogenic signaling that requires detailed study.
Exosomal cargo transfer between HSC occurs as a result of the direct binding of exosomes to the surface of the recipient HSC. An improved understanding of the molecular basis for exosome interactions with target HSC may provide unique opportunities to exploit this natural delivery mechanism for improving efficacy or targeting of antifibrotic agents. The purpose of these studies was to identify cell surface molecules that mediate functional binding of HSC-derived exosomes to recipient HSC.
Materials and methods

Animal procedures
Animal protocols were approved by the Institutional Animal Care and Use Committee of Nationwide Children's Hospital (Columbus, OH, USA). Male FVB mice (6-8 weeks) (n = 10) were injected intraperitoneally three times each week for 5 weeks with either 30 lL of vegetable oil or a mixture of 0.5 lL carbon tetrachloride (CCl 4 ; Sigma-Aldrich, St Louis, MO, USA) in 29.5 lL of vegetable oil. Mice were then injected via the tail vein with 40 lg of PKH26-labeled HSC-derived exosomes and 4 h later, animals were sacrificed. Livers lobes were either perfused for subsequent isolation of HSC or hepatocytes, or immediately harvested along with the other major body organs for fluorescence imaging using a Xenogen IVIS 200 (PerkinElmer, Waltham, MA, USA).
Primary mouse HSC or hepatocytes
Livers from exosome-treated mice were perfused in situ and then subjected to either collagenase digestion for isolation of hepatocytes [19] or pronase/collagenase digestion and buoyant-density centrifugation for isolation of HSC [17] . Hepatocytes or HSC were maintained in, respectively, complete William E medium (Gibco, Billings, MT, USA) or DMEM/F12/10% FBS for 24 h and then analyzed by confocal microscopy for the presence of PKH26.
For in vitro exosome binding studies, hepatocytes or HSC were isolated from Swiss Webster mice as described above and maintained in primary culture for up to, respectively, 72 h or passage 6 (P6; 1 : 3 split every 5 days). Binding assays were performed on cells seeded at 5000 cells/well in 8-well multi-chamber slides (Falcon, Caroll, OH, USA).
Purification of HSC-derived exosomes
Exosomes were removed from FBS by serial ultracentrifugation [20] prior to using it for HSC culture. Exosomes were isolated from conditioned medium of P6 HSC using standardized steps of low and ultraspeed centrifugation [20] . Nanoparticle tracking analysis (Nanosight TM , Malvern Instruments, Westborough, MA, USA) was used to determine exosome size and frequency. Exosomes were further evaluated for morphology and size using a Tecnai G2 F20 cryogenic transmission electron microscope (FEI; Hillsboro, Oregon, OR, USA) as described [17] . For some experiments, HSC were treated with 500 nM SYTO RNASelect TM Green Fluorescent Cell Stain (Thermo Fisher Scientific, Waltham, MA, USA) for 12 h and then incubated in fresh medium (exosome-free) for 48 h prior to exosome isolation. For other experiments, miR-199a-5p mimic (Qiagen, Germantown, MD, USA) was labeled with Cy3 dye using a Label II Ò miRNA labeling kit (Mirus Bio LLC, Madison, WI, USA) and then transfected into exosomes by electroporation using a Nucleofector kit (Lonza, Koln, Germany); exosomes were then repurified using a PureExo kit (101Bio, Palo Alto, CA, USA).
Exosome binding assays
Exosomes from control or SYTO-RNA-labeled HSC or that contained Cy3-miR-199a-5p were labeled for 1 h with 4 lM of the fluorescent lipophilic membrane dyes PKH26 or PKH67, according the manufacturer's specifications (Sigma-Aldrich). Exosomes (0-4 lgÁmL À1 ) or free Cy3-labeled miR-199a-5p (1 lM) were added for up to 48 h to primary mouse HSC or hepatocytes which were then washed in PBS and imaged using a confocal microscope (Zeiss, Obercochen, Germany) or lysed in lysis buffer (Boston Bioproducts, Ashland, MA, USA) and measured at 590/540 nm using a Spectra Max Ò M2 microplate reader (VWR, Atlanta, GA, USA) to assess levels of PKH26 fluorescence. Prior to exosome addition in some experiments, HSC were stained with PKH67 (Sigma-Aldrich) and hepatocytes were stained with far red (Sigma-Aldrich). In some binding experiments, HSC were pretreated or coincubated with 0-100 lgÁmL À1 RGD or RGE tripeptides (American Peptide, Sunnyvale, CA, USA), 0-100 lM EDTA (SigmaAldrich), 0-10 lM sodium chlorate (Sigma-Aldrich), 0-10 lM sodium sulfate (Sigma-Aldrich), 0-10 lgÁmL À1 rabbit anti-mouse integrin avb3 IgG (Bioss Inc, Woburn, MA, USA), or 0-20 lgÁmL À1 rat anti-mouse integrin a5b1 IgG (Millipore, Temecula, CA, USA) or 0-10 lgÁmL À1 rat anti-mouse integrin aM, (CD11b; Novus Biologicals, Littleton, CO, USA). For antibody studies, nonimmune IgG was used as a negative control.
Integrin knockdown
Small interfering RNA (siRNA) to mouse integrin avo r b1, or negative controls were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). To avoid off-target effects, the siRNA preparations consisted of three targetspecific 20-25 nucleotide siRNA. Primary mouse HSC (10 5 -10 6 cells) were transfected with 100 nM siRNA by electroporation using a Nucleofector Kit (Lonza) and incubated for 12 h in medium containing 10% FBS which was then replaced with fresh medium. Our previous data have shown a 40% transfection efficiency of siRNA in primary mouse HSC using this approach [12] . Integrin knockdown was confirmed by RT-PCR (see Table 1 for primer sequences) or western blot analysis of cell lysates using anti-avb3 or anti-a5b1 with anti-b-actin (Abcam, Cambridge, MA, USA) serving as a loading control [12, 13, 17] .
Cells were then used for exosome binding analysis as described above.
Regulation of CCN2-3 0 UTR by miR-214-enriched exosomes
The full-length 997 bp 3 0 -UTR of mouse CCN2 was subcloned into a Fire-Ctx sensor lentivector (SBI, Mountain View, CA, USA), downstream of the Firefly luciferase reporter and cytotoxin (CTX) drug sensor genes as described [17] . Recipient HSC were transfected with parental or CCN2 3 0 -UTR vectors for 24 h prior to 1-h incubation with RGD, IgG, anti-integrin avb3 or anti-integrin a5b1. Cells were then incubated for 24 h in the presence of exosomes isolated from Day 1 HSC which we previously showed are highly enriched in miR-214 which directly targets the CCN2 3 0 -UTR [17] . To control transfection efficiency, the cells were also transfected with 0.8 lg pRL-CMV vector (Promega, Madison, WI, USA) containing Renilla luciferase reporter gene. Luciferase activity was measured in triplicate using an E1910 Dual Luciferase Reporter Assay System (Promega). Renilla luciferase activity was used for normalization, and Firefly luciferase activity in exosome-treated cells was compared to that in nontreated cells.
HSC coculture system
One well of a 2-well microculture system (Ibidi Inc., Verona, WI, USA) [12, 13, 17] received exosome donor P6 HSC that had been transfected with 100 nM pre-mir-214 (Life Technologies, Carlsbad, CA, USA). Some cells were cultured with 10 lM GW4869, an inhibitor of neutral sphingomyelinase 2 which is required for exosome biogenesis [21, 22] . After 12 h, the other well was seeded with P6 HSC transfected with parental miR-Selection Fire-Ctx lentivector or the same vector containing either wild-type or mutant CCN2 3 0 -UTR lacking the miR-214 binding site [17] . After 12 h, direct communication between the cells was initiated and proceeded for 24 h. In some experiments, 100 lgÁmL À1 heparin sulfate or 100 lgÁmL À1 chondroitin sulfate were included in the culture medium. Luciferase activity was measured in triplicate using the Dual Luciferase Reporter Assay System. Firefly luciferase activity in pre-mir-21-transfected cells was compared to that in nontransfected cells, with Renilla luciferase activity used for normalization. Integrin av (mouse)
Cell adhesion assay ) for 30 mins at 37°C as described [23] . The added cells were primary mouse activated HSC (see above) or Day 9 primary mouse bone-marrow-derived macrophages that were obtained as described [24] . Prior to addition to the CCN2-coated wells, cells were preincubated for 30 mins with 10-20 lgÁmL À1 anti-integrin antibodies or nonimmune IgG. Wells were washed three times with PBS and adherent cells were fixed with 10% formalin and quantified using CyQUANT GR dye [23] . 
Immunoctyochemistry
Heparin-affinity
One hundred micrograms of HSC exosomes were added to 120 lL TSKgel heparin-5PW affinity beads (Tosoh BioScience LLC, King of Prussia, PA, USA) in 200 lL PBS and mixed at 37°C for 1 h. The beads were washed three times with 1 mL PBS and then split into 10 equal aliquots which were then mixed for 15 mins with 200 lL PBS containing 0.15-2.5 M NaCl. The beads were collected by centrifugation, washed twice in 200 lL of their respective NaCl treatment, and then extracted into 20 lL2 9 SDS/ PAGE sample buffer, with boiling for 5 mins. 18 lLo f each sample was subjected to SDS/PAGE and analyzed by western blot with anti-CD81 (Pro-Sci, Fort Collins, CO, USA), using a chemiluminscent detection kit (Promega) to visualize immunoreactive protein.
Statistical analysis
Data from binding assays, RT-PCR, western blots, cellular fluorescence or luciferase activity assays are reported as the mean AE SEM. Statistical significance was analyzed using Student's t-test and P < 0.05 was considered statistically significant. All statistical analyses were performed using SIGMA PLOT 12.0 software (SPSS Inc., Chicago, IL, USA).
Results
Cellular binding of HSC-derived exosomes
Exosomes isolated from P6 mouse HSC had a mean diameter of 144 nm as assessed by nanoparticle tracking analysis and were bimembrane vesicles as assessed by cryogenic transmission electron microscopy (Fig. 1A) . These features were consistent with our earlier reports in which we demonstrated HSC exosomes to have a mean diameter of 140 nm as assessed by dynamic light scattering, to carry a net charge of À26 mV, and to express the exosome markers, CD9, CD81, and flotillin-1 [12, 13, 17] . Exosomes were then labeled with the lipophilic fluorescent dye PKH26 so that their interactions with target cells could be visualized and quantified. As shown in Fig. 1B (Fig. 1C ) that resulted in delivery into the cells of their RNA cargo which became separated from the exosomal membrane components between 5 and 24 h after addition to the cells (Fig. 1D) . Uptake into recipient cells of exosomal miR-199a-5p similarly resulted in its distinct localization in the cells as compared to exosomal membrane stain and was effectively delivered into the cells, unlike free miR-199a-5p (Fig. 1E) . Exosomes bound strongly to primary cultures of HSC but not to hepatocytes, a phenomenon that was apparent in either individual cultures of each cell type, or in cocultures of both cell types (Fig. 1F) . To verify that these findings faithfully reflected the preferential binding of exosomes to activated HSC in vivo, we analyzed the hepatic localization of systemically injected exosomes. As shown in Fig. 1G , within 4 h of tail vein injection, exosomes had accumulated mainly within CCl 4 -injured livers to the exclusion of the other organ systems. Examination of isolated liver cells from control or CCl 4 -treated mice revealed that the exosomes had bound to the HSC population, with essentially nondetectable binding to hepatocytes (Fig. 1H) . Based on their preferential binding to HSC both in vitro and in vivo, subsequent binding studies of HSC-derived exosomes were performed using activated HSC in vitro.
Role of integrins in exosome binding to HSC
Binding of exosomes to HSC was dose-dependently blocked by inclusion of RGD in the incubation medium during a 12-h binding experiment, the specificity of which was demonstrated by the inability of RGE to block exosome binding ( Fig. 2A) . Preincubation of the target HSC for 1 h with RGD, followed by extensive rinsing to remove excess peptide, also resulted in reduced exosome binding, whereas preincubation with RGE was ineffective (Fig. 2B) . Since the RGD-sensitivity and specificity of exosome binding suggested a possible involvement of cell surface integrins, many of which require divalant cations for function, binding experiments were also performed in the presence of EDTA with the result that 50-100 lM EDTA inhibited exosome binding to HSC over 24 h (Fig. 2C) . To address the possible functional role of integrins avo r b1, HSC were transfected with siRNA to either or both subunits for 24 h prior to incubation with exosomes for the subsequent 24 h. This treatment, which resulted in decreased levels of avo rb1 mRNA of 78% or 75%, respectively, and of avo rb1 protein levels of 75% or 90%, respectively (Fig. 2D) , caused > 95% of exosome binding to be blocked by the siRNAs, either individually or collectively (Fig. 2E ). Since we have previously documented the expression and function of integrins avb3o ra5b1 in activated HSC [23, 26] , we examined their possible role in exosome binding. We first confirmed the functionality of neutralizing anti-integrin avb3 or anti-integrin a5b1 antibodies by demonstrating that they blocked adhesion of HSC to CCN2 as previously reported [23, 26] ( Fig. 2F) . We next showed that these antibodies also caused a dose-dependent decrease in exosome binding, with > 90% inhibition at 4 lgÁmL À1 anti-avb3o r 20 lgÁmL À1 anti-a5b1 (Fig. 2G) . The specificity of this outcome was confirmed using an antibody to integrin aM which neither blocked exosome binding to HSC (Fig. 2G) nor HSC binding to CCN2 (Fig. 2F) but nonetheless blocked macrophage adhesion to CCN2 (Fig. 2F ) consistent with the absence of integrin aM in quiescent or activated HSC [27] and the role of integrin aM as a CCN2 adhesion receptor for macrophages [28, 29] . Collectively, the antibody neutralization studies demonstrated a specific functional role for integrin avb3 and integrin a5b1 in mediating exosome binding to HSC.
The inhibitory action of exosomal miR-214 on CCN2 3
0 -UTR activity [17] was blocked by RGD, anti-integrin avb3 or anti-integrin a5b1, but not by nonimmune IgG (Fig. 2H) . Furthermore, the ability of exosomes from quiescent HSC to suppress production of aSMA, collagen 1(a1), or CCN2 in activated HSC was also blocked by anti-integrin avb3 or anti-integrin a5b1 (Fig. 2I) . Collectively, these data show that cell surface integrins avb3o ra5b1 are required for exosomal delivery of regulatory miRs into HSC and downstream phenotypic reprogramming in the recipient cells, which includes inhibition of activation-and fibrosis-associated gene expression. ) for 1 h and excess peptide was removed by extensive washing prior to addition of PKH26-stained HSC exosomes (red) for 24 h. The cells were analyzed by confocal microscopy (209)( upper; showing a representative experiment) or by fluorescence intensity of cell lysates (lower; n = 5, *P < 0.001 versus 0 lgÁmL À1 RGD, student's t-test). (C) PKH26-stained exosomes (red) were incubated with primary mouse HSC (green) for 24 h with 0-100 lM EDTA. Cells were analyzed by confocal microscopy (209)( left; showing a representative experiment) or fluorescence in cell lysates was determined spectrophotometrically (right; n = 5, *P < 0.001 versus 0 lM EDTA, student's t-test). (D) HSC were transfected for 24 h with integrin avo rb1 siRNA and analyzed for expression of avo rb1 mRNA by RT-PCR (left; n = 9, *P < 0.001 versus Ctrl, student's t-test) or levels of their corresponding proteins by western blot using anti-integrin avb3 (center) or anti-integrin a5b1 antibodies (right) for which b-actin was used a loading control (n = 9, *P < 0.001 versus Ctrl, student's t-test). 'Ctrl' represents cells treated with a scrambled siRNA sequence. (E) Mouse HSC were transfected for 24 h with siRNA to the integrin avo rb1 subunits, either individually or together. Cells were then stained with PKH-67 (green) for 1 h and incubated with PKH26-stained exosomes (red) for 24 h. Blue, 4 0 ,6-diamidino-2-phenylindole. Data are representative of three experiments. (F) Adhesion of mouse HSC or macrophages to a CCN2 substrate after preincubation of the cells with neutralizing anti-integrin avb3 (10 lgÁmL
), anti-integrin aM (10 lgÁmL À1 ), or their nonimmune IgG counterparts (at the same respective dose). n = 5, *P < 0.001 versus Ctrl, student's t-test. (G) Mouse HSC were preincubated with neutralizing anti-integrin avb3, a5b1o raM IgG or nonimmune IgG for 1 h prior to addition for 24 h of PKH26-stained HSC exosomes. Cells were analyzed by confocal microscopy (209)( upper; showing a representative experiment) or by spectrophotometric quantification of fluorescence in cell lysates (lower; n = 6, *P < 0.001. +P < 0.05 versus Ctrl, student's t-test). (H) Recipient HSC were transfected with a parental or CCN2 3 0 -UTR luciferase reporter vector for 24 h prior to 1-h incubation with RGD, IgG, anti-integrin avb3, or anti-integrin a5b1. Cells were then incubated for 24 h in the presence of miR-214-enriched exosomes as described [17] . Exosome-mediated suppression of luciferase activity was inhibited by RGD or anti-integrin avb3. n = 9, *P < 0.001 versus Ctrl, student's t-test. (I) Immunocytochemical detection of CCN2, aSMA or collagen a1 in activated HSC alone ('Ctrl') or after 36-h incubation with exosomes from D1-3 HSC, in the presence or absence of anti-integrin avb3 or anti-integrin a5b1. Data are representative of three experiments.
Role of cell surface heparin-like molecules in exosome binding to HSC As shown in Fig. 3A , incubation of exosomes with HSC was inhibited in a dose-dependent manner when heparin sulfate, but not chondroitin sulfate, was included in the incubation medium. Furthermore, pretreatment of the HSC with sodium chlorate to selectively reduce sulfation of heparan sulfate proteoglycans (HSPG) resulted in an inhibition of exosome binding (Fig. 3B) . This outcome was reversed by coincubation of the cells with sodium sulfate to rescue them from the chlorate block (Fig. 3B) . Finally, the biological significance of HSPG-exosome interactions ). The inhibition of CCN2 3 0 -UTR activity by miR-214-enriched exosomes was reversed by GW4869 or heparin, but not by chondroitin sulfate. n = 9, *P < 0.001 versus ctrl, student's t-test. (D) Heparin-affinity beads were mixed with exosomes (1 h, room temp) prior to washing in PBS and mixing with different NaCl concentrations. The figure shows the extraction of residual exosomes from the heparin beads using sample buffer as assessed by SDS/PAGE and western blot for the exosome-specific marker, CD81. The CD81 signal was not affected by 0-0.5 M NaCl (data not shown). n = 6, *P < 0.001; +P < 0.05 versus 0.5 M NaCl, student's t-test.
was determined using a HSC-HSC coculture system that allows exosomal communication between neighboring HSC to be examined under normal conditions of endogenous exosome production and action [12, 17] . As we have reported [17] , coculture of miR-214-transfected donor HSC with CCN2 3 0 -UTR luciferase reporter-transfected recipient HSC resulted in miR-214-dependent regulation of the CCN2 3
0 -UTR reporter, the exosome-dependency of which was shown by the ability of the exosome inhibitor, GW4869, to reverse the suppressed CCN2 3 0 -UTR activity (Fig. 3C) . Addition of heparin sulfate to the coculture also reversed miR-214-suppressed CCN2 3 0 -UTR activity, whereas chondroitin sulfate was ineffective showing that exosomal cargo signaling in the recipient cells was heparin-dependent. Collectively, these data show that downstream cell surface HSPG on HSC are functional receptors for HSC-derived exosomes. To confirm the heparin-binding property of exosomes, they were incubated with heparin-affinity beads in a cell-free system with the result that they bound strongly and required 1.0 M NaCl for their efficient elution (Fig. 3D ).
Discussion
In this study, we identified integrins and HSPG as cell surface molecules that are required for binding of HSC-derived exosomes to HSC. Specifically, we showed that integrin avb3o ra5b1 in HSC is required for exosome binding, miR uptake, and functional reprogramming in the cells. This represents a novel function for integrin avb3 in HSC which has previously been shown to support cell survival, adhesion to CCN2, periostin-dependent activation, and osteopontin-dependent collagen up-regulation [23, 26, [30] [31] [32] , all of which reflect the enhanced expression and a central role for integrin avo ravb3 in HSC function and hepatic fibrosis [33] [34] [35] . Similarly, integrin a5b1 in activated HSC is associated with cell adhesion to fibronectin or CCN2, or fibronectin-dependent survival, cytoskeletal rearrangements or expression of matrix metalloproteases or collagen I [26, [36] [37] [38] [39] , but its role in binding and mediating functional effects of HSC-derived exosomes is novel. Integrin b1 on HSC also engages exosomes from liver sinusoidal endothelial cells [40] suggesting that exosomes from different cell types may compete for common integrin receptors on the same target HSC. Also, we cannot yet exclude the possibility that exosome binding involves either other b1 integrins (e.g. integrin avb1o ra8b1, which are RGD-sensitive and expressed by HSC [41, 42] ) or other RGD-sensitive integrins (e.g. integrins avb5, avb6, avb8, or IIbb3). Integrin aLb2 on CD8 + dendritic cells or activated T cells was shown to engage ICAM-1 on dendritic cell-secreted exosomes [43, 44] but other studies have demonstrated a role for exosomal integrins in interacting with target cells [45] [46] [47] [48] [49] [50] [51] [52] [53] so it will be of interest in the future to determine if exosomal integrins also contribute to exosome-HSC binding interactions. Heparan sulfate proteolgycans are a family of proteins substituted with glycosaminoglycan polysaccharides that interact broadly with diverse extracellular ligands, although their precise functional interactions are predominantly determined by the extent and site of side chain sulfation [54] [55] [56] . HSPG regulate cell growth, proliferation, adhesion, motility and signaling through their ability to act as high capacity low affinity coreceptors for many ligands that are consequently able to interact more efficiently with their specific cognate high affinity receptors [57, 58] . Cell surface HSPG bound to HSC-derived exosomes as evidenced by the competition studies in which exosome binding to HSC was blocked by coincubation with heparin sulfate or by preincubation of recipient HSC with sodium chlorate which selectively reduces sulfation of HSPG glycan chains during their biosynthesis in the Golgi apparatus by competitively binding to 3 0 -phosphoadenosine-5 0 -phosphosulfate synthase at the active site [59, 60] . This effect is reversible in the presence of excess sodium sulfate, a characteristic that allowed the chlorate-induced block of exosome binding to HSC to be rescued. Overall, these data demonstrate a requirement for HSPG sulfation for exosome binding and the cellular (rather than exosomal) localization of the HSPG component. While cell surface HSPG in HSC play a functional role in binding CCN2 by acting as coreceptors in association with integrin avb3, integrin a5b1, or low density lipoprotein receptor-related protein [23, 26, 61] , our data reveal an additional role for HSPG in HSC as functional exosome receptors that are required for the downstream action of exosomal miR-214 in target HSC. These findings are similar to the heparin-dependent binding of U-87 glioblastoma cell-derived exosomes to U-87 or CHO cells [62] , although our results show that heparin-binding mechanisms are not restricted to exosomes from cancer cells. Since activated human HSC synthesize the HSPG core proteins syndecans 1-4, perlecan, and glypican [63] and syndecan-2 and glypican-1 are associated with internalized glioblastoma exosomes in U-87 cells [62] , it will be of interest in future studies to determine which HSPG core proteins are involved in HSC exosome binding.
While we have identified integrin avb3, integrin a5b1, and HSPG as important receptors for HSCderived exosomes and portals for exosomal cargo uptake, the involvement of these molecules in the highly specific localization of HSC-derived exosomes to HSC in HSC-hepatocyte cocultures in vitro or to HSC in fibrotic liver in vivo remains to be established. That said, integrin avb3 expression in activated HSC has been mechanistically exploited for selective targeting of candidate antifibrotic or cytotoxic agents in experimental liver fibrosis [64] [65] [66] . The intrinsic specificity of HSC-derived exosomes for HSC suggests that such exosomes, or the molecular binding partners on their outer surface, may be exploited for targeted delivery of therapeutic drugs to activated HSC in fibrotic livers. Similar translational applications have been proposed for delivery of drugs with targeted actions to cancer cells using the HSPG-binding properties of cancer cell-derived exosomes [62] . Continued analysis of the binding partners involved in the interaction of HSC-derived exosomes with their target HSC will yield important information about the underlying mechanisms involved and their potential for use in targeted drug delivery. Furthermore, continued characterization of suppressive signaling molecules (including but not limited to miR-214 and miR-199a-5p) in exosomes from quiescent HSC offers a new direction for identifying novel antifibrotic agents. 
